Local excision after neoadjuvant chemoradiotherapy versus total mesorectal excision: a case‐matched study in 110 selected high‐risk patients with rectal cancer

• Published in: Colorectal disease 2020-12, Vol.22 (12), p.1999-2007
• Main Authors: Calmels, M., Collard, M. K., Cazelles, A., Frontali, A., Maggiori, L., Panis, Y.
• Format: Article
• Language: English
• Subjects: Body mass index; Cancer; Chemoradiotherapy; Local excision; local recurrence; Morbidity; organ preservation; rectal cancer; Rectum; TEM; Tumors
• ISSN: 1462-8910; 1463-1318
• DOI: 10.1111/codi.15323

Aim The aim of this comparative study was to report a 10‐year experience of an organ preservation strategy by local excision (LE) in selected high‐risk patients (aged patients and/or patients with severe comorbidity and/or indication for abdominoperineal excision) versus total mesorectal excision (TME) after neoadjuvant radiochemotherapy (RCT) for patients with locally advanced (T3–T4 and/or N+) low and mid rectal cancer with suspicion of complete tumour response (CTR) or near‐CTR. Method Thirty‐nine patients with rectal cancer who underwent LE after RCT for suspicion of CTR were matched to 71 patients who underwent TME according to body mass index, gender, tumour location and ypTNM stage. Operative, oncological and functional results were compared between groups. Results In the LE group, ypT0, ypTis or ypT1N0R0 were noted in 28/39 (72%). Overall morbidity was observed in 10/39 (26%) in LE vs 46/71 in the TME group (65%) (P = 0.001). Severe morbidity (Clavien–Dindo ≥ 3) was noted in 1/39 patients from the LE group (3%) vs 3/71 (4%) from the TME group (P = 1.000). After a mean follow‐up of 63 ± 4 months (range 56–70 months), local recurrence was noted in 2/39 (5%) from the LE group vs 2/71 (3%) from the TME group (P = 0.601). Definitive stoma was noted in 2/39 (6%) from the LE group vs 8/71 (12%) from the TME group (P = 0.489). Major low anterior resection syndrome was noted in 5/23 (22%) from LE group vs 11/33 (33%) from the TME group (P = 0.042). Conclusion The accuracy of response prediction after RCT was 72% after LE. In high‐risk patients, LE represents a safe alternative to TME with better functional results and the same long‐term oncological outcome.